CAPTRUST Financial Advisors
FBRX icon

CAPTRUST Financial Advisors’s Forte Biosciences FBRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49
Closed -$2K – 2716
2022
Q2 		$2K Hold
49
– – ﹤0.01% 4450
2022
Q1 		$2K Sell
49
-3
-6% -$114 ﹤0.01% 4476
2021
Q4 		$3K Buy
52
+3
+6% +$202 ﹤0.01% 4270
2021
Q3 		$4K Buy
+49
New +$27.1K ﹤0.01% 4022

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAPTRUST Financial Advisors's FBRX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Forte Biosciences (FBRX) in Q3 2022, closing a stake of 49 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in FBRX in Q3 2021 and held it in 4 quarters. The position peaked at $4K in Q3 2021. 33 funds tracked by Wall St. Rank hold FBRX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Forte Biosciences position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 49 Forte Biosciences shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Forte Biosciences in Q3 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Forte Biosciences position peaked at $4K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.